Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05519137 · ClinicalTrials.gov registry record · NA

Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia

A NA study of Alzheimers Disease, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
14
Enrollment target
1
Study location

NCT05519137: Completed NA study of Alzheimers Disease, sponsored by Icahn School of Medicine at Mount Sinai.

NCT05519137 is a NA study of Alzheimers Disease that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 14 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05519137, a NA study of Alzheimers Disease, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

To test the effect of a tailored lighting intervention controlled by the Readings At Desk (RAD) controller on sleep and mood in Alzheimer's disease participants.

Primary Outcome

The Pittsburgh Sleep Quality Index (PSQI) is composed of 19 items that generate 7 component scores. The sum of the 7 component scores yields a single global score with a range of 0 to 21. A global score \>5 is considered to indicate sleep disturbances. A lower global score indicates improvement in sleep disturbance.

Conditions Studied

Interventions

  • DEVICE Active lighting intervention
  • DEVICE Control lighting intervention

Study Locations (1)

New York

  • Light and Health Research Center - Menands

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2022-01-06
Est. Completion 2023-05-01
Phase NA

What the finished NCT05519137 record still lists

NCT05519137 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Active lighting intervention is the first listed.

NCT05519137 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05519137 about?

NCT05519137 is a clinical study titled "Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia". To test the effect of a tailored lighting intervention controlled by the Readings At Desk (RAD) controller on sleep and mood in Alzheimer's disease participants.

What is the current status of trial NCT05519137?

This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2022-01-06. Estimated completion is 2023-05-01.

What conditions does trial NCT05519137 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT05519137?

The interventions under investigation include: Active lighting intervention (DEVICE), Control lighting intervention (DEVICE).

Who is sponsoring clinical trial NCT05519137?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05519137 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05519137's enrollment target sits among peer trials

14 137th of 147 higher than 10 of 147 other Alzheimers Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT05519137, the US trial registry maintained by the National Library of Medicine. NCT05519137 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.